表皮生长因子受体（EGFR）抑制用于复发性或转移性头颈部鳞状细胞癌。 - Suppr

Suppr

超能文献

EGFR inhibition for recurrent or metastatic HNSCC.

作者信息

Argiris Athanassios

机构信息

Hygeia Hospital, Athens, Greece; University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

出版信息

Lancet Oncol. 2015 May;16(5):488-9. doi: 10.1016/S1470-2045(15)70178-6. Epub 2015 Apr 16.

DOI:10.1016/S1470-2045(15)70178-6

PMID:25892143

Abstract

摘要

相似文献

EGFR inhibition for recurrent or metastatic HNSCC.表皮生长因子受体（EGFR）抑制用于复发性或转移性头颈部鳞状细胞癌。

Lancet Oncol. 2015 May;16(5):488-9. doi: 10.1016/S1470-2045(15)70178-6. Epub 2015 Apr 16.

Head and neck cancer: second-line afatinib shows promise.头颈癌：二线阿法替尼显示出前景。

Nat Rev Clin Oncol. 2015 Jul;12(7):373. doi: 10.1038/nrclinonc.2015.86. Epub 2015 May 5.

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.阿法替尼与甲氨蝶呤用于老年二线复发和/或转移性头颈部鳞状细胞癌患者的疗效比较：LUX-Head & Neck 1试验的亚组分析

Ann Oncol. 2016 Aug;27(8):1585-93. doi: 10.1093/annonc/mdw151. Epub 2016 Apr 15.

Oral metronomic chemotherapy in recurrent, metastatic and locally advanced head and neck cancers.口服节拍化疗用于复发性、转移性和局部晚期头颈癌

Clin Oncol (R Coll Radiol). 2013 Jun;25(6):388. doi: 10.1016/j.clon.2013.01.002. Epub 2013 Feb 20.

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.生物标志物预测阿法替尼相较于甲氨蝶呤二线治疗复发性和/或转移性头颈部鳞癌患者可带来更好的临床结局。

Ann Oncol. 2017 Oct 1;28(10):2526-2532. doi: 10.1093/annonc/mdx344.

Combination therapy with bevacizumab and temsirolimus in squamous cell carcinoma of the head and neck.贝伐单抗与替西罗莫司联合治疗头颈部鳞状细胞癌。

Oral Oncol. 2013 Aug;49(8):e25. doi: 10.1016/j.oraloncology.2013.04.001. Epub 2013 Apr 28.

Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.阿法替尼作为复发性/转移性头颈部鳞状细胞癌二线治疗药物：LUX-Head and Neck 1 试验中治疗依从性、安全性和阿法替尼给药方式的亚组分析。

Oral Oncol. 2019 Oct;97:82-91. doi: 10.1016/j.oraloncology.2019.08.004. Epub 2019 Aug 23.

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].吉非替尼与静脉注射甲氨蝶呤治疗复发性头颈部鳞状细胞癌的III期研究[校正后]

J Clin Oncol. 2009 Apr 10;27(11):1864-71. doi: 10.1200/JCO.2008.17.0530. Epub 2009 Mar 16.

Carboplatin in combination with raltitrexed in recurrent and metastatic head and neck squamous cell carcinoma: A multicentre phase II study of the Gruppo Oncologico Dell'Italia Meridionale (G.O.I.M.).卡铂联合雷替曲塞治疗复发和转移性头颈部鳞状细胞癌：意大利南部肿瘤协作组（G.O.I.M.）的一项多中心II期研究

Anticancer Res. 2005 Nov-Dec;25(6C):4445-9.

Cetuximab and methotrexate in recurrent or metastatic head and neck squamous cell carcinoma-A single institution analysis of 54 patients.西妥昔单抗与甲氨蝶呤治疗复发或转移性头颈部鳞状细胞癌——单机构54例患者分析

Clin Otolaryngol. 2019 Jul;44(4):639-643. doi: 10.1111/coa.13316. Epub 2019 Apr 1.

引用本文的文献

MAGI2-AS3 hypermethylated in promoter region promotes migration and invasion of head and neck squamous cell carcinoma via miRNA-31-5p/AR axis.启动子区域高甲基化的MAGI2-AS3通过miRNA-31-5p/AR轴促进头颈部鳞状细胞癌的迁移和侵袭。

Transl Oncol. 2025 Feb;52:102223. doi: 10.1016/j.tranon.2024.102223. Epub 2024 Dec 7.

Blocking β2-AR and Inhibiting COX-2: A Promising Approach to Suppress OSCC Development.阻断β2-肾上腺素能受体并抑制环氧化酶-2：一种抑制口腔鳞状细胞癌发展的有前景的方法。

Int Dent J. 2025 Apr;75(2):807-816. doi: 10.1016/j.identj.2024.06.014. Epub 2024 Jul 22.

Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.头颈部鳞状细胞癌的当前靶向治疗对肿瘤微环境的修饰。

J Exp Clin Cancer Res. 2023 May 5;42(1):114. doi: 10.1186/s13046-023-02691-4.

SFRP1 in Skin Tumor Initiation and Cancer Stem Cell Regulation with Potential Implications in Epithelial Cancers.SFRP1 在皮肤肿瘤起始和癌症干细胞调控中的作用及其在上皮性癌症中的潜在意义。

Stem Cell Reports. 2020 Feb 11;14(2):271-284. doi: 10.1016/j.stemcr.2019.12.006. Epub 2020 Jan 9.

Knockdown of LncRNA Inhibits Cell Migration, Invasion and Proliferation in Head and Neck Squamous Cell Carcinoma.长链非编码RNA的敲低抑制头颈部鳞状细胞癌的细胞迁移、侵袭和增殖。

J Cancer. 2019 Jul 5;10(17):4000-4008. doi: 10.7150/jca.29029. eCollection 2019.

MicroRNA-141 suppresses growth and metastatic potential of head and neck squamous cell carcinoma.微小RNA-141抑制头颈部鳞状细胞癌的生长和转移潜能。

Aging (Albany NY). 2019 Feb 8;11(3):921-932. doi: 10.18632/aging.101791.

Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.靶向肿瘤细胞和免疫检查点受体的治疗性抗体联合使用的原理：通过IgG1同种型免疫效应刺激来利用先天免疫和适应性免疫。

Cancer Treat Rev. 2018 Feb;63:48-60. doi: 10.1016/j.ctrv.2017.11.008. Epub 2017 Dec 2.

EGFR and Cortactin: Markers for potential double target therapy in oral squamous cell carcinoma.表皮生长因子受体（EGFR）与皮层肌动蛋白：口腔鳞状细胞癌潜在双靶点治疗的标志物

Exp Ther Med. 2017 Nov;14(5):4620-4626. doi: 10.3892/etm.2017.5120. Epub 2017 Sep 18.

Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.基于全局蛋白质组学的胸腺素β-4 X 连锁蛋白鉴定及其对头颈鳞状细胞癌预后标志物的验证。

Sci Rep. 2017 Aug 22;7(1):9031. doi: 10.1038/s41598-017-09539-w.

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.复发性和/或转移性头颈部鳞状细胞癌的循证治疗选择

Front Oncol. 2017 May 9;7:72. doi: 10.3389/fonc.2017.00072. eCollection 2017.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验